These stocks are supported by both solid fundamentals and strong technical positions.
Abbott also reports promising results ahead of a big medical meeting.
The company raises sales guidance while reporting better-than-expected Q3 earnings.
Although Abbott has recently gained on positive trial results, Gilead Sciences remains in the forefront of the market.
Shares dip on news that the FDA needs more review time.
The company's Abraxane delays tumor growth in patients with advanced melanoma.
The Swiss pharmaceutical has several very strong potential oncology drugs, most of which could be commercially successful.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.